What? When? Why?

Latest Happenings in Business World

Share on



Global Autoinjectors Market Size, Share, COVID-19 Impact Analysis

Individuals worldwide are currently picking autoinjectors to build self-reliance and keep away from communication with medical services experts. It assisted with expanding the organic market alongside the creation of the market. The biologics to biosimilar move that include autoinjector is attributed to giving cheaper alternatives to the drawn-out treatment patients that open a gainful chance for the market. The COVID-19 pandemic has been quickening the pattern of self-infusion, engaging patients to have greater inclusion and command over their treatment. Fresher innovations in the autoinjectors market have empowered this pattern, as they permit better administration of infusion speed, infusion site agony, and treatment tension.

Autoinjectors Market Size (2020 to 2025)

As per the recent research report published by Market Data Forecast, the global autoinjectors market is forecasted to worth USD 5.93 billion by 2025.

What are autoinjectors?

An auto-injector is a little, pen-formed gadget containing a hypodermic needle utilized to convey a fixed portion of medication to patients. The medication is conveyed by embedding the needle at the ideal site of infusion and a catch press. For the most part, the site of inclusion relies on the idea of the medication to be controlled, but the intramuscular route is the favored route of the administration. Many of these auto-injector systems are spring-loaded, pre-filled syringes used for severe allergic reactions, often known as anaphylaxis or anaphylactic shock, and rheumatoid instances arthritis and multiple sclerosis, among others. The auto-injector is a user-friendly interface built for the patient and untrained self-administration. Autoinjectors are commonly used for epinephrine self-administration (preventing anaphylaxis), migraine patients (immediate pain relief), or surgical and emergency care. The utilization of auto-injector has brought numerous advantages for both the patient and medical care proficient, including diminishing needle-related fear issues, diminishing dangers of needle stuck mishaps, guaranteeing measurement quality congruity aiding increment viability.

Also, it has worked on self-administration, diminished uneasiness, improved wellbeing, and improved consistency. For instance, most of the illness adjusting drugs at present accessible available for the treatment of various sclerosis are conveyed by infusion. This has long been seen as a source of anxiety for a significant number of patients and a big cause of non-compliance with care. Autoinjectors can address this issue by guaranteeing that the infusion is made at the precise profundity and can unmistakably improve administration solace and decency when contrasted with manual needles. Information from different clinical preliminaries upholds auto-injectors' utilization, which shows that they improve adherence and lessen the needle size of the more modest measure altogether. Needles are safely discarded or usually sealed during solo use, with the possibility of incidental needle sticks or possible needles being reused. When used accurately, these pre-filled gadgets guarantee the proper dosage of the medication. Regarding the auto-injector's ease of use, the gadgets are accessible in a re-usable and expendable structure. Autoinjector advancements enable patients, especially first-time patients, to infuse themselves with medications with lower error rates and less stress. These gadgets limit or eliminate needle connections, eliminating critical adhesion obstruction in some patients.


Rising anaphylaxis cases are the major driver for the global autoinjectors market.

The mounting prevalence of anaphylaxis and food allergen and intensifying demand for adrenaline, epinephrine autoinjectors worldwide drive the growth of the global autoinjectors market. Anaphylaxis is a severe, life-threatening allergic reaction to food, medications, latex, and Hymenoptera stings, and Epinephrine is the first line in anaphylaxis therapy. Pharmaceutical firms are designing highly advanced epinephrine auto-injectors (EAIs) for anaphylaxis. Technological developments include revolutionary prototypes, wearable epinephrine systems for children, larger adults, auto-injectors with increased temperature tolerance and longer shelf life for epinephrine, impact and weather-resistant casings, and devices that warn patients that the dosage has been successfully given. Factors considered to enhance auto-injectors include safety cap removal force, needle activation force, override force, ejection dosage, needle weight, ejection time, dose setting & audible click detection. Such technological advances improve the adoption of auto-injectors.

Moreover, the mounting event of persistent and way of life-related sicknesses, expanding the number of administrative endorsements, escalating patient attentiveness and inclination of patients regarding self-administration, mounting self-medicine practice, and promising repayments and government financing, ascend in R&D endeavors by organizations to create basic, savvy, and new innovation-based autoinjectors for therapy of ongoing infections like rheumatoid joint pain and numerous sclerosis, Patent expiry of biologics are likewise encouraging the development for the autoinjectors market.

The tendency for elective medication conveyance modes like epinephrine nasal sprays and oral diabetic specialists and oral insulin, deficiency of appropriate preparation for devouring autoinjectors, high cost of injectors, and improvement of autoinjectors for numerous medication viscosities are the significant difficulties for the development of autoinjectors market.

Avail sample market brochure of the report @ https://www.marketdataforecast.com/market-reports/autoinjectors-market/request-sample


The COVID-19 pandemic has brought about a worldwide medical care emergency, causing a move in medical care conveyance in many regions. Most trivial systems and in-clinic treatments were conceded in the primary portion of 2020 to prevent the spread of the contamination and facilitate the cost for medical services foundation. After limitations were facilitated, there has been a general decrease in patients deferring looking for care and treatment in medical care settings. Additionally, the slowdown in clinical trial recruitment has deferred the introduction of new treatments. These elements might adversely affect the autoinjectors market, particularly with their utilization in medical services organizations in mid-2020.

Nonetheless, in contrast to numerous different enterprises, the auto-injector business also benefited from COVID 19 pandemic. The interest in autoinjectors has ascended to lessen face-to-face communication with wellbeing experts and self-oversee at home. While there are numerous limitations inferred on various areas, there are no limitations in the medical services industry that helped get the worldwide auto-injectors market immaculate.

The interest for successful home consideration and distant checking has expanded the significance of autoinjectors for patients to helpfully and effectively oversee constant sicknesses and sensitivities without visiting the clinic. This has been particularly obvious in cases of diabetes, Crohn's infection, and rheumatoid joint pain patients depending on prefilled needles and autoinjectors to deal with their condition at home.

Also, With the spread of COVID 19, the utilization of autoinjectors has expanded around the world. The development on the lookout for epinephrine autoinjectors likewise influenced this market. After the pandemic, the autoinjectors market is required to develop more with the rising interest in drugs. Likewise, the medical services industry got financing from the public authority during the pandemic to help examine and innovative headways later on.

The report can be customized as per requirements; ask for it @ https://www.marketdataforecast.com/market-reports/autoinjectors-market/customization


Key players in the global autoinjectors market cater to the demand for these devices by investing in technologically innovative technologies in their global product range. Teva Pharmaceutical Industries Ltd, Abbvie, Novartis AG, SHL Medical, Consort Medical, Mylan, and Ypsomed AG, Owen Mumford, Becton, Dickinson and Company, Amgen, Haselmeier, ELI Lilly, Johnson and Johnson, N.V., Scandinavian Health Limited, and Antares Pharma are the key players offering autoinjectors.

Most organizations are foreseen to grow their business possibilities in the approaching a long time by improving their item portfolios and delivering item separation. These include, In Feb 2020, Teva launches Ajovy auto-injector device, and In Jan 2020, UMN and Windgap Medical collaborate to design a cyanide antidote autoinjector.


WRITTEN BY: Market Data Forecast

Market Data Forecast